Alessa Therapeutics

$43.6Mtotal raised · 5 rounds on record
$25.4Mlatest round · Venture round · Apr 2025 · 18 mo ago
$799kgrants · 2 grants · CORDIS
50+team · employees, estimated range

Overview

Alessa Therapeutics is developing a proprietary drug-delivery platform for sustained and localized release of clinically proven therapies to effectively treat early-stage prostate cancer.

Funding and backers

Total raised
$43.6M
5 rounds on record
Latest round
$25.4M
Venture round · Apr 2025 · 18 mo ago
Team
51-200
employees, estimated range
Grants
$799k
2 grants · CORDIS
The money's age
Due for its next round
18 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 21, 2025 New executive Alessa Therapeutics Appoints Cam Gallagher as President & Chief Executive Officer · alessatherapeutics.com Oct 21, 2025 Recognition Alessa Therapeutics is a 2020 Leadership Forum and HealthTech Showcase Finalist · alessatherapeutics.com Apr 18, 2025 Raised a round Venture round $25.4M · SEC Form D Dec 19, 2024 Raised a round Seed $15M · Pulse 2.0 Aug 1, 2023 Won a grant $406k · CORDIS Aug 4, 2021 Won a grant $394k · CORDIS Jan 2, 2020 Board appointment Peter Parker, Director · SEC Form D Dec 19, 2019 Raised a round Venture round $3.3M · SEC Form D 2018 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Apr 2025 $25.4M — SEC Form D
Seed Dec 2024 $15M — Pulse 2.0
Grant Aug 2023 $406k — CORDIS
Grant Aug 2021 $394k — CORDIS
Venture round Dec 2019 $3.3M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Alessa Therapeutics, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Zachary CollinsExecutive OfficerSEC Form D
Cam GallagherExecutive Officer, DirectorSEC Form D
John MaroneyExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs treble
Hub71
backs BioSapien
Soma Capital
backs treble
High-Tech Gründerfonds
backs Draupnir Bio
SOSV
backs BioSapien
VentureSouq
backs treble
Similar startupsby what they do, their industry and backers
Mercury BioVenture round $2.4M · 13 mo ago · 51-200 employees
With a focus on advanced bio-molecular drug delivery systems, Mercury Bio is developing the therapeutic technologies to help more people…
BioSapienSeed $1.8M · 4 yr ago · 11-50 employees
BioSapien's MediChip™ delivers sustained cancer therapy directly at the tumor site while minimizing systemic exposure through localized…
Draupnir BioSeed $13M · 2 yr ago
Draupnir Bio is developing new innovative therapies for patients.
Mongoose BioVenture round $1M · 3 yr ago · Founded 2023 · 51-200 employees
Delivering clinically proven epigenetically programmed memory T Cells to fight cancer. Mongoose Bio is an early-stage clinical company…
Biokier11-50 employees
About Us BioKier Inc. is an early-stage pharmaceutical company developing new proprietary medical foods and drugs for diabetes and related…
SyncromuneVenture round $144.8M · 23 mo ago · 51-200 employees
Syncromune® is developing SYNC-T®, a platform immunotherapy designed to synchronize the location of 3 key components needed to educate the…

Financials

Total raised
$44.4M
Latest round
Venture - Series Unknown
Funding rounds
5
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $25.4M Details
Seed 2024 $15M Details
Grant 2023 $406k Details
Grant 2021 $394k Details
Venture - Series Unknown 2019 $3.3M Details

People

Zachary Collins
Executive Officer
SEC Form D
Cam Gallagher
Executive Officer, Director
SEC Form D
John Maroney
Executive Officer, Director
SEC Form D
Steve Tregay
Director
SEC Form D
Douglas Crawford
Director
SEC Form D
Annie Mitsak
Director
SEC Form D
Richard Lim
Director
SEC Form D
Pamela Munster
Director
SEC Form D
Peter Parker
Director
SEC Form D
Doug Crawford
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

News

Blog 4 months ago
Alessa Therapeutics Receives Positive FDA Feedback Following Type C Meeting on Enolen's Pivotal Phase 3 Trial Design
FDA Confirms Single Study with Primary Endpoint of Progression-Free Survival Sufficient for NDA Company expects to begin pivotal Phase 3 trial in mid-2027
Read more
Report
Award 6 months ago
Alessa Therapeutics Announces Enolen Phase 1 Study Presentation Receives "Best Poster" Award at the American Urological Association Annual Meeting
SAN CARLOS, CA - May 29, 2026 - Alessa Therapeutics (
Read more
Report
Award menafn 6 months ago
Alessa Therapeutics Announces Enolen Phase 1 Study Presentation Receives
Alessa Therapeutics Announces Enolen Phase 1 Study Presentation Receives
Read more
Report
Blog 6 months ago
Alessa Therapeutics Appoints Dr. Peter Carroll and Dr. Neal Shore to Lead Clinical Advisory Board
Internationally Renowned Prostate Cancer Researchers to Support Continued Clinical Advancement of Enolen SAN CARLOS, CA - May 22, 2026 - Alessa Therapeutics (
Read more
Report
Blog 8 months ago
Alessa Therapeutics Announces Positive Preliminary Safety and Efficacy Data from Enolen Phase 1 Trial
First study to demonstrate safe and selective administration of sustained and localized delivery of enzalutamide
Read more
Report
News YahooFinance 8 months ago
Alessa Therapeutics Announces Positive Preliminary Safety and Efficacy Data from Enolen Phase 1 Trial
SAN CARLOS, Calif., March 16, 2026--Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, announced the presentation of positive pre
Read more
Report
Blog 10 months ago
Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, A First-Of-Its-Kind Treatment for Localized Prostate Cancer
Fast Track Designation Highlights Potential of Enolen to Address Unmet Medical Need for Patients with Low to Intermediate Risk, Localized Prostate Cancer Company Expects to Provide Initial Findings from Enolen's Phase 1 Trial Later This Year SAN CARLOS, C
Read more
Report
News YahooFinance 10 months ago
Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, A First-Of-Its-Kind Treatment for Localized Prostate Cancer
SAN CARLOS, Calif., January 08, 2026--Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, today announced that the U.S. Food and D
Read more
Report
News markets.financialcontent.com 10 months ago
Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, A First-Of-Its-Kind Treatment for Localized Prostate Cancer
Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, A First-Of-Its-Kind Treatment for Localized Prostate Cancer
Read more
Report
Press release marketwatch.com 10 months ago
Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, A First-Of-Its-Kind Treatment for Localized Prostate Cancer Read more
Report
Show more news

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Carlos United States
HQ
Contact Us
50-200 est. staff
930 Brittan Avenue, San Carlos, California 94070
company site